German Cannabis Prescription Study's 16.3% Figure Draws Scrutiny
A Hanf Magazin analysis says the headline 16.3 percent number in a German medical cannabis prescription study doesn't describe all physicians, and the denominator matters.

Woman doctor with stethoscope writing at desk with laptop and notes.
The 16.3 percent number doesn't mean what the headline implies
Hanf Magazin's analysis, published Nov. 22, 2026, says the study's 16.3 percent figure cannot be read as a share of all German physicians. The piece, titled "16.3 Percent, But Not From All Doctors," focuses on what the study actually measures rather than how the number travels in headlines.
The signal available to CannIntel is the headline and publication details of that analysis. We haven't reviewed the underlying study, its methodology or its sample, and we won't characterize them beyond what Hanf Magazin's title states.
That caveat is the story. A single percentage can be accurate and still mislead.
Why the denominator decides everything
The cleanest read on any prescribing statistic is to ask who is in the denominator. A share of all physicians, a share of physicians in a given specialty and a share of physicians who treat a qualifying condition are three different measurements, and each one produces a different business conclusion.
Hanf Magazin's framing implies the study's base population is narrower than the full physician pool. If so, the 16.3 percent describes a subset, and extrapolating it to the national doctor workforce would overstate prescriber penetration.
Not a small error. It changes the size of the addressable prescriber base.
What this means for the German market read
Operators and investors sizing German medical demand should treat prescriber-penetration figures as conditional until the sampling frame is clear. Germany's medical cannabis channel runs through physician prescriptions, so the number of active prescribers feeds directly into patient access, pharmacy volumes and import demand.
An inflated read of prescriber participation can push forecasts too high. A deflated one can undersell a market where the real constraint may be concentration among a relatively small group of willing prescribers rather than broad physician uptake.
That second possibility deserves attention. If prescribing is clustered, patient access depends on a thin layer of doctors, and any shift in that layer (regulatory, reimbursement-driven or reputational) moves volumes faster than a broad-based market would.
How to read prescriber statistics without getting burned
The same discipline applies to every prescribing study that reaches a headline. Before a figure goes into a model, a pitch deck or a policy argument, the reader should be able to answer a short list of questions:
- Which physicians were counted, and which were excluded?
- Does the percentage describe prescribers, prescriptions or patients?
- What time window does the data cover?
Trade press has a habit of stripping those qualifiers in the rush to a clean number. Hanf Magazin's piece is a useful reminder that the qualifier is often the finding.
What we don't know yet
CannIntel has not independently verified the study's design, authorship, sample size or data source. The signal doesn't name the research team or institution, and it doesn't supply the study's own definition of the physician group behind the 16.3 percent.
Readers tracking German prescribing data should go to the study itself and to Hanf Magazin's full analysis for the methodology. Any figure that circulates without its denominator is unfinished.
For broader context on how prescription data shapes the German channel, see the CannIntel topic hub on German medical cannabis prescriptions. Germany's market is tracked alongside regulatory moves from agencies such as the BfArM, and prescriber counts feed directly into how analysts model patient access.
Watch next for whether the study's authors or other German outlets clarify the physician base behind the 16.3 percent, and whether the figure keeps circulating without it.
Frequently asked questions
What does the 16.3 percent figure refer to?
According to Hanf Magazin's Nov. 22, 2026 analysis, the figure is not a share of all German doctors. CannIntel has not reviewed the underlying study, so the precise physician group it covers should be confirmed against the study itself.
Why does the denominator matter in a prescribing study?
A percentage of all physicians, of one specialty, or of treating physicians describes different populations. Using the wrong base can overstate or understate prescriber participation, which affects demand forecasts and policy arguments.
How does this affect the German medical cannabis market?
German medical cannabis flows through physician prescriptions, so the number and concentration of prescribers influence patient access, pharmacy volumes and import demand. Misreading prescriber penetration can skew market sizing.
Has CannIntel verified the study's findings?
No. CannIntel's reporting is based on Hanf Magazin's headline and publication details. We have not independently reviewed the study's design, authorship, sample size or data source.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Medical

Report links cannabis use disorder to higher odds of suicidal thoughts
An Earth.com report ties cannabis use disorder to elevated suicidal ideation, adding a mental-health data point to the legalization debate as dispensaries and regulators weigh messaging.

Italy Plans to Double Military Cannabis Greenhouses by 2028
Rome's military pharmaceutical plant targets at least 700 kilograms of annual cannabis output by 2028, a step in Italy's state-run medical supply model.

MediPharm Prepares European Launch of Cannabis Inhaler
A Newsweed report says MediPharm is readying a cannabis inhaler for European markets, but the signal supplies no launch date, country list or financial terms.
More from the newsroom

Canadian Province Advances Bill Allowing 20-Year Cannabis Store Licenses
A provincial bill moving through a Canadian legislature would let cannabis retail licenses run up to two decades, a sharp break from the short-term permits that now govern the market.

Federal Hemp Rule to Tighten Minnesota THC Sales, Wisevoter Reports
A federal hemp rule would squeeze Minnesota's THC market, a report says, and the real fight is over total-THC math, not labels.

Federal Hemp-Derived THC Ban Looms; Operators Weigh Exit Options
A federal ban on intoxicating hemp-derived THC is nearing its effective date, reshaping a market built on the 2018 Farm Bill's definitional gap.